NVNO
enVVeno Medical Corporation
Set alert
- YTD
- -40.07%
- 1 year
- -72.42%
- Open
- 6.87
- Prev close
- 7.02
- Mkt cap
- 4.68M
- Vol
- 19.18K
- Avg vol
- 28.14K
- EPS
- -24.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.70
- High
- 7.11
- Forward P/E
- -2.45
- Beta
- 1.22
- Short ratio
- 4.12
- Inst. own
- 29.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 31, 2024
- 50-d avg
- 3.22
- 200-d avg
- 4.62
- 1y target
- 18.00
Key statistics
- Market cap
- 51.03M
- Enterprise value
- -3.57M
- Trailing P/E
- 0.00
- Forward P/E
- -2.45
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.08
- EPS (TTM)
- -1.29
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -9.84M
- Total cash
- 48.38M
- Total debt
- 1.15M
- Return on equity
- -58.77%
- Shares outstanding
- 17.54M
- Short % of float
- 2.74%
- 50-day average
- 3.22
- 200-day average
- 4.62
Analyst view
Consensus: none
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Jul 31, 2024
Expected Jul 31, 2024. Consensus EPS estimate -0.35.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | 0.00 | -0.35 | — | — |
| Jul 31, 2024 | Jun 1, 2024 | 0.00 | -0.31 | — | — |
| Jul 31, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | -0.31 | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | 0.00 | -0.32 | — | — |
About enVVeno Medical Corporation
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- envveno.com
News
- enVVeno Medical Q3 EPS $(6.29) Misses $(3.27) Estimate
- enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
- enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
- enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
- enVVeno Announces Publication Of Peer-Reviewed Health Economics Study Supporting Venous Valve Therapy; Findings May Support Future Coverage And Reimbursement Decisions
- Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
- enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
- enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
- enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
- enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
Your note
Sign in to keep a note on NVNO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALAVI HAMED | Chief Technology Officer | Sale | Mar 12, 2024 | 0 |
| BERMAN ROBERT ANDREW | Chief Executive Officer | Purchase | Dec 18, 2024 | 222,236 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kingdon Capital Management LLC | 4.90% | 859,261 | 2.50M | Sep 29, 2024 |
| Perceptive Advisors Llc | 3.96% | 694,315 | 2.02M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.40% | 596,917 | 1.74M | Sep 29, 2024 |
| Vanguard Group Inc | 3.36% | 589,141 | 1.71M | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 2.42% | 425,000 | 1.24M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 1.99% | 348,263 | 1.01M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.39% | 418,536 | 1.22M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.89% | 156,171 | 454.46K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 75,500 | 219.71K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 23,984 | 69.79K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.14% | 23,879 | 69.49K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.12% | 20,487 | 59.62K | Oct 30, 2024 |